Bextra Study Links Drug To Increased Risk Of Heart Attacks & Strokes

Bextra Study Links Drug To Increased Risk Of Heart Attacks & Strokes

On April 7, 2005, Pfizer suspended sales of its arthritic drug Bextra (or valdecoxib), a pain reliever used to treat osteoarthritis, adult rheumatoid arthritis and severe menstrual cramps, on requests by the U.S. Food and Drug Administration and European regulators. Bextra was pulled from the market due to concerns that patients taking the drug were at an increased risk of having heart attacks, strokes and a potentially fatal skin condition called Stevens-Johnson syndrome (known to cause inflammation of the mucous membranes of the mouth, throat, genitals, intestinal tract, and membrane lining the eyelids) and that those potentially fatal side effects outweighed the benefits of the drug. A team of class action attorneys has launched an investigation into the Bextra situation to find out what rights individuals who have taken Bextra may have against the company. If you or your loved ones have ever taken Bextra, and have experienced any of these side effects while taking the drug, you may be entitled to money.**

Fill out the form on the right for a free attorney review.